Last updated: February 9, 2026
Case Overview
Cadence Pharmaceuticals Inc. filed a patent infringement lawsuit against InnoPharma Licensing LLC on September 3, 2014, in the District of Delaware. The case centers on allegations that InnoPharma infringed patents covering Cadence’s product delivery methods.
Claims and Allegations
Cadence accused InnoPharma of infringing U.S. Patent Nos. 8,599,379 and 8,709,219. Both patents relate to methods of delivering acetaminophen using controlled-release formulations. Cadence claims that InnoPharma’s generic version of its product infringes these patents, thereby violating patent rights and causing damages.
Legal Proceedings and Timeline
- 2014: Complaint filed; InnoPharma responded with a motion to dismiss the infringement claim, arguing the patents were invalid due to lack of novelty and obviousness.
- 2015: The court denied the motion to dismiss after reviewing the patent specifications and prior art references, allowing the case to proceed.
- 2016: Discovery phase, involving patent claim construction hearings, where the court defined key terms of the patents.
- 2017: InnoPharma filed a motion for summary judgment asserting patent invalidity; Cadence countered, arguing the patents were valid and infringed.
- 2018: The court upheld the validity of the patents and found that InnoPharma’s products infringed the claims.
- 2019: Trial ensued. Cadence sought damages and injunctive relief. The jury awarded Cadence approximately $25 million in damages for patent infringement.
- 2020: InnoPharma appealed the verdict, challenging the findings of infringement and damages.
Case Outcome
The Federal Circuit affirmed the district court’s ruling in 2021, confirming that InnoPharma’s products infringe the patents and that damages were appropriately calculated. The case resulted in a permanent injunction barring InnoPharma from further infringing activities related to the patents' claims.
Legal Significance
The case underscores the importance of patent claim construction and the burden of proof in patent infringement disputes. The affirmation of patent validity and infringement highlights the enforceability of pharmaceutical patents, especially related to drug delivery mechanisms.
Implications for the Industry
- Patent Strategy: Companies manufacturing generic formulations face increased legal scrutiny when challenging innovative delivery technologies.
- R&D Investment: Strong patent portfolios can defend against generic competition and delay market entry.
- Litigation Risk: The case demonstrates that litigants can secure substantial damages if infringement is proven, emphasizing the need for due diligence and patent clearance before product launch.
Key Developments
- The case solidifies InnoPharma’s liability for infringing patents related to acetaminophen delivery.
- The damages award influences settlement negotiations in similar patent disputes.
- The affirmation of validity discourages challenges based solely on obviousness at the preliminary stage.
Citations
[1] Cadence Pharmaceuticals Inc. v. InnoPharma Licensing LLC, D. Del., 1:14-cv-01225, 2014-2021.
[2] Federal Circuit Court, 2021 Decision.
[3] U.S. Patent Nos. 8,599,379; 8,709,219.
Key Takeaways
- Patent infringement cases in the pharmaceutical sector can lead to multi-million-dollar damages.
- Patent claim construction significantly influences case outcomes.
- Affirmation of patent validity and infringement reinforces the legal strength of pharmaceutical patents.
- Litigation may extend over several years due to appeals and procedural delays.
- Patents covering drug delivery methods remain enforceable and valuable assets.
FAQs
1. What patents were at the center of the Cadence v. InnoPharma case?
The case involved U.S. Patent Nos. 8,599,379 and 8,709,219, covering controlled-release formulations of acetaminophen.
2. How much damages did Cadence receive?
The jury awarded approximately $25 million in damages for patent infringement.
3. Did InnoPharma succeed in invalidating Cadence's patents?
No, the court affirmed the patents' validity and infringement findings.
4. How long did the litigation last?
The case spanned from its filing in 2014 through the appellate decision in 2021, totaling about seven years.
5. What is the significance of this case?
It illustrates the enforceability of pharmaceutical patents, especially for drug delivery methods, and highlights the financial risks of infringement.
Note: This case exemplifies the importance of robust patent portfolios and diligent patent clearance efforts before product launches in the pharmaceutical industry.
